← Search

Journal of Political Economy Vol. 133 No. 2 2025

Targeting Precision Medicine: Evidence from Prenatal Screening

Peter Conner1,2,3,4,5; Liran Einav1,2,3,4,5; Amy Finkelstein1,2,3,4,5; Petra Persson1,2,3,4,5

1 National Bureau of Economic Research · 2 Karolinska Institutet · 3 Massachusetts Institute of Technology · 4 Research Institute of Industrial Economics · 5 Stanford University

Abstract

We study the introduction of a noninvasive prenatal screening—cell-free DNA (cfDNA) screening—which is used to target a more costly invasive test that elevates miscarriage risk. Using Swedish administrative data, we document that coverage of cfDNA substantially increases cfDNA screening and reduces invasive testing. We develop and estimate a stylized model of prenatal choices and find that narrow targeting of cfDNA coverage can improve outcomes and reduce costs, while broader coverage also improves outcomes but with increased costs. These findings point to the potential gains from well-designed targeting of screening but at the same time highlight the importance of the targeting design.

DOI
10.1086/732893
Volume
133
Issue
2
Pages
604-651
Language
en
Sources
bibtex:phds-export.bib openalex crossref

Cite